165 related articles for article (PubMed ID: 1358620)
1. Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects.
Mattila MJ; Kuitunen T; Plétan Y
Eur J Clin Pharmacol; 1992; 43(2):179-84. PubMed ID: 1358620
[TBL] [Abstract][Full Text] [Related]
2. Diazepam effects on the performance of healthy subjects are not enhanced by treatment with the antihistamine ebastine.
Mattila MJ; Aranko K; Kuitunen T
Br J Clin Pharmacol; 1993 Mar; 35(3):272-7. PubMed ID: 8097102
[TBL] [Abstract][Full Text] [Related]
3. Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects.
Rohatagi S; Gillen M; Aubeneau M; Jan C; Pandit B; Jensen BK; Rhodes G
Int J Clin Pharmacol Ther; 2001 Mar; 39(3):126-34. PubMed ID: 11396753
[TBL] [Abstract][Full Text] [Related]
4. Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): a randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults.
Antonijoan R; García-Gea C; Puntes M; Pérez J; Esbrí R; Serra C; Fortea J; Barbanoj MJ
Clin Ther; 2007 May; 29(5):814-822. PubMed ID: 17697901
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects.
Yamaguchi T; Hashizume T; Matsuda M; Sakashita M; Fujii T; Sekine Y; Nakashima M; Uematsu T
Arzneimittelforschung; 1994 Jan; 44(1):59-64. PubMed ID: 7907873
[TBL] [Abstract][Full Text] [Related]
6. Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects.
Vincent J; Sumner DJ; Reid JL
Br J Clin Pharmacol; 1988 Nov; 26(5):503-8. PubMed ID: 2905151
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment.
Noveck RJ; Preston RA; Swan SK
Clin Pharmacokinet; 2007; 46(6):525-34. PubMed ID: 17518511
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.
Lasseter KC; Dilzer SC; Vargas R; Waldman S; Noveck RJ
Clin Pharmacokinet; 2004; 43(2):121-9. PubMed ID: 14748620
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and electrocardiographic effect of ebastine in young versus elderly healthy subjects.
Huang MY; Argenti D; Wilson J; Garcia J; Heald D
Am J Ther; 1998 May; 5(3):153-8. PubMed ID: 10099053
[TBL] [Abstract][Full Text] [Related]
10. Cimetidine does not influence the metabolism of the H1-receptor antagonist ebastine to its active metabolite carebastine.
Van Rooij J; Schoemaker HC; Bruno R; Reinhoudt JF; Breimer DD; Cohen AF
Br J Clin Pharmacol; 1993 Jun; 35(6):661-3. PubMed ID: 8101096
[TBL] [Abstract][Full Text] [Related]
11. Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects.
Chaikin P; Gillen MS; Malik M; Pentikis H; Rhodes GR; Roberts DJ
Br J Clin Pharmacol; 2005 Mar; 59(3):346-54. PubMed ID: 15752381
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects.
Vincent J; Liminana R; Meredith PA; Reid JL
Br J Clin Pharmacol; 1988 Nov; 26(5):497-502. PubMed ID: 2905150
[TBL] [Abstract][Full Text] [Related]
13. The effects of single and repeated administration of ebastine on cognition and psychomotor performance in comparison to triprolidine and placebo in healthy volunteers.
Hindmarch ; Shamsi Z
Curr Med Res Opin; 2001; 17(4):273-81. PubMed ID: 11922401
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetics of the histamine H1-receptor antagonist ebastine and its active metabolite carebastine in rats, guinea pigs, dogs and monkeys.
Matsuda M; Sakashita M; Mizuki Y; Yamaguchi T; Fujii T; Sekine Y
Arzneimittelforschung; 1994 Jan; 44(1):55-9. PubMed ID: 7907872
[TBL] [Abstract][Full Text] [Related]
15. Acute and subchronic effects of the H1-histamine receptor antagonist ebastine in 10, 20 and 30 mg dose, and triprolidine 10 mg on car driving performance.
Brookhuis KA; De Vries G; De Waard D
Br J Clin Pharmacol; 1993 Jul; 36(1):67-70. PubMed ID: 8104017
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis.
Frank H; Gillen M; Rohatagi SS; Lim J; George G;
J Clin Pharmacol; 2002 Oct; 42(10):1097-104. PubMed ID: 12362923
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic studies of the histamine H1-receptor antagonist ebastine in dogs.
Puigdemont A; Queralt M; Jansat JM; Martinez-Tobed A
J Pharm Pharmacol; 1994 Jul; 46(7):596-9. PubMed ID: 7996390
[TBL] [Abstract][Full Text] [Related]
18. Placebo controlled comparison of acute effects of ebastine and clemastine on performance and EEG.
Hopes H; Meuret GH; Ungethüm W; Leopold G; Wiemann H
Eur J Clin Pharmacol; 1992; 42(1):55-9. PubMed ID: 1347267
[TBL] [Abstract][Full Text] [Related]
19. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats.
Fujii T; Matsumoto S; Amejima H; Hatoyama T; Nakao M; Kagemoto A; Tanaka K; Miyazaki H
Arzneimittelforschung; 1994 Apr; 44(4):527-38. PubMed ID: 7912071
[TBL] [Abstract][Full Text] [Related]
20. Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine.
Tagawa M; Kano M; Okamura N; Higuchi M; Matsuda M; Mizuki Y; Arai H; Iwata R; Fujii T; Komemushi S; Ido T; Itoh M; Sasaki H; Watanabe T; Yanai K
Br J Clin Pharmacol; 2001 Nov; 52(5):501-9. PubMed ID: 11736858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
